Patents by Inventor Timothy Kogan

Timothy Kogan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10521277
    Abstract: Transactional Lock Elision allows hardware transactions to execute unmodified critical sections protected by the same lock concurrently, by subscribing to the lock and verifying that it is available before committing the transaction. A “lazy subscription” optimization, which delays lock subscription, can potentially cause behavior that cannot occur when the critical sections are executed under the lock. Hardware extensions may provide mechanisms to ensure that lazy subscriptions are safe (e.g., that they result in correct behavior). Prior to executing a critical section transactionally, its lock and subscription code may be identified (e.g., by writing their locations to special registers). Prior to committing the transaction, the thread executing the critical section may verify that the correct lock was correctly subscribed to. If not, or if locations identified by the special registers have been modified, the transaction may be aborted.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: December 31, 2019
    Assignee: Oracle International Corporation
    Inventors: David Dice, Timothy L. Harris, Alex Kogan, Yosef Lev, Mark S. Moir
  • Publication number: 20190258508
    Abstract: A computer system including one or more processors and persistent, word-addressable memory implements a persistent atomic multi-word compare-and-swap operation. On entry, a list of persistent memory locations of words to be updated, respective expected current values contained the persistent memory locations and respective new values to write to the persistent memory locations are provided. The operation atomically performs the process of comparing the existing contents of the persistent memory locations to the respective current values and, should they match, updating the persistent memory locations with the new values and returning a successful status. Should any of the contents of the persistent memory locations not match a respective current value, the operation returns a failed status. The operation is performed such that the system can recover from any failure or interruption by restoring the list of persistent memory locations.
    Type: Application
    Filed: February 13, 2019
    Publication date: August 22, 2019
    Inventors: Virendra J. Marathe, Matej Pavlovic, Alex Kogan, Timothy L. Harris
  • Patent number: 6683103
    Abstract: Thienylsulfonamides and their pharmaceutically acceptable derivatives, pharmaceutical compositions, articles of manufacture, combinations, lyophilized powders and methods for the treatment of endothelin diseases using these formulations and sulfonamides are provided. A process of preparing an alkali metal salt of a hydrophobic sulfonamide is provided. The process includes the step of dissolving a free sulfonamide in an organic solvent in the presence of a saturated alkali metal salt solution and recovering the formed sulfonamide salt from the organic phase.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: January 27, 2004
    Assignee: Texas Biotechnology Corporation
    Inventors: Chengde Wu, Natalie Blok, Timothy Kogan, Karin Keller
  • Publication number: 20030208084
    Abstract: Thienyl-, furyl- and pyrrolyl-sulfonamides, formulations of pharmaceutically-acceptable salts thereof and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides, formulations thereof and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit the activity of endothelin are also provided.
    Type: Application
    Filed: May 28, 2003
    Publication date: November 6, 2003
    Inventors: Chengde Wu, Bore Gowda Raju, Timothy Kogan, Natalie Blok, Patricia Woodard
  • Patent number: 6632829
    Abstract: Thienyl-, furyl- and pyrrolyl-sulfonamides, formulations of pharmaceutically-acceptable salts thereof and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides, formulations thereof and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit the activity of endothelin are also provided.
    Type: Grant
    Filed: November 5, 2001
    Date of Patent: October 14, 2003
    Assignee: Texas Biotechnology Corp.
    Inventors: Chengde Wu, Bore Gowda Raju, Timothy Kogan, Natalie Blok, Patricia Woodard
  • Patent number: 6613804
    Abstract: Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.
    Type: Grant
    Filed: December 4, 2001
    Date of Patent: September 2, 2003
    Assignee: Encysive Pharmaceuticals, Inc.
    Inventors: Ming Fai Chan, Timothy Kogan, Erik Joel Verner, Adam Kois, Vitukudi Narayanaiyengar Balaji
  • Patent number: 6458805
    Abstract: Formulations of pharmaceutically-acceptable salts of thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides using the formulations are provided. In particular, formulations of sodium salts of N-(isoxazolyl)-thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)-pyrrolylsulfonamides and methods using these sulfonamide salts for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide salt are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamide salts or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: October 1, 2002
    Assignee: Texas Biotechnology Corporation
    Inventors: Natalie Blok, Chengde Wu, Patricia Woodard, Karin Keller, Timothy Kogan
  • Patent number: 6432994
    Abstract: Thienyl-, furyl- and pyrrolyl-sulfonamides, pharmaceutically-acceptable salts of sulfonamides, formulations of salts and the sulfonamides, and methods for modulating or altering the activity of the endothelin family of peptides using the formulations and sulfonamides are provided. In particular, formulations of sodium salts of N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides are provided. A process of preparing an alkali metal salt of a hydrophobic sulfonamide is provided. The process includes the step of dissolving a free sulfonamide in an organic solvent in the presence of a saturated alkali metal salt solution and recovering the formed sulfonamide salt from the organic phase.
    Type: Grant
    Filed: March 27, 2000
    Date of Patent: August 13, 2002
    Assignee: Texas Biotechnology Corporation
    Inventors: Chengde Wu, Natalie Blok, Timothy Kogan, Karin Keller, Patricia Woodard
  • Publication number: 20020095041
    Abstract: Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.
    Type: Application
    Filed: December 4, 2001
    Publication date: July 18, 2002
    Inventors: Ming Fai Chan, Timothy Kogan, Erik Joel Verner, Adam Kois, Vitukudi Narayanaiyengar Balaji
  • Patent number: 6420567
    Abstract: Thienyl-, furyl- and pyrrolyl-sulfonamides, formulations of pharmaceutically-acceptable salts thereof and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides, formulations thereof and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit the activity of endothelin are also provided.
    Type: Grant
    Filed: September 26, 1997
    Date of Patent: July 16, 2002
    Assignee: Texas Biotechnology Corporation
    Inventors: Chengde Wu, Bore Gowda Raju, Timothy Kogan, Natalie Blok
  • Publication number: 20020091272
    Abstract: Thienyl-, furyl- and pyrrolyl-sulfonamides, formulations of pharmaceutically-acceptable salts thereof and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides, formulations thereof and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit the activity of endothelin are also provided.
    Type: Application
    Filed: November 5, 2001
    Publication date: July 11, 2002
    Inventors: Chengde Wu, Bore Gowda Raju, Timothy Kogan, Natalie Blok, Patricia Woodard
  • Publication number: 20020091270
    Abstract: Thienylsulfonamides and their pharmaceutically acceptable derivatives, pharmaceutical compositions, articles of manufacture, combinations, lyophilized powders and methods for the treatment of endothelin diseases using these formulations and sulfonamides are provided. A process of preparing an alkali metal salt of a hydrophobic sulfonamide is provided. The process includes the step of dissolving a free sulfonamide in an organic solvent in the presence of a saturated alkali metal salt solution and recovering the formed sulfonamide salt from the organic phase.
    Type: Application
    Filed: December 20, 2001
    Publication date: July 11, 2002
    Inventors: Chengde Wu, Natalie Blok, Timothy Kogan, Karin Keller, Patricia Woodard
  • Patent number: 6342610
    Abstract: Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: January 29, 2002
    Assignee: Texas Biotechnology Corp.
    Inventors: Ming Fai Chan, Chengde Wu, Bore Gowda Raju, Timothy Kogan, Erik Joel Verner, Rosario Silvestre Castillo, Venkatachalapathi Yalamoori, Adam Kois, Vitukudi Narayanaiyengar Balaji
  • Patent number: 6331637
    Abstract: N-alkyl, N-alkenyl, N-alkynyl, N-aryl and N-fused bicyclo or tricyclo thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, (phenyl) and (phenoxy)thienylsulfonamides, (phenyl) and (phenoxy)furylsulfonamides, and (phenyl) and (phenoxy)pyrrolylsulfonamides and methods of using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.
    Type: Grant
    Filed: March 22, 1999
    Date of Patent: December 18, 2001
    Assignee: Texas Biotechnology Corporation
    Inventors: Ming Fai Chan, Chengde Wu, Bore Gowda Raju, Timothy Kogan, Adam Kois, Erik Joel Verner, Rosario Silvestre Castillo, Venkatachalapathi Yalamoori, Vitukudi Narayanaiyengar Balaji
  • Publication number: 20010039289
    Abstract: Formulations of pharmaceutically-acceptable salts of thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides using the formulations are provided. In particular, formulations of sodium salts of N-(isoxazolyl)-thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)-pyrrolylsulfonamides and methods using these sulfonamide salts for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide salt are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamide salts or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.
    Type: Application
    Filed: February 23, 2001
    Publication date: November 8, 2001
    Inventors: Natalie Blok, Chengde Wu, Patricia Woodard, Karin Keller, Timothy Kogan
  • Publication number: 20010021714
    Abstract: Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)-furylsulfonamides and N-(isoxazolyl)pyrrolyisulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prod rugs thereof that inhibit or increase the activity of endothelin are also provided.
    Type: Application
    Filed: November 7, 1997
    Publication date: September 13, 2001
    Inventors: MING FAI CHAN, CHENGDE WU, BORE GOWDA RAJU, TIMOTHY KOGAN, ERIK JOEL VERNER, ROSARIO SILVESTRE CASTILLO, VENKATACHALAPATHI YALAMOORI, ADAM KOIS, VITUKUDI NARAYANAIYENGAR BALAJI
  • Patent number: 6248767
    Abstract: Formulations of pharmaceutically-acceptable salts of thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides using the formulations are provided. In particular, formulations of sodium salts of N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamide salts for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide salt are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamide salts or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.
    Type: Grant
    Filed: September 26, 1997
    Date of Patent: June 19, 2001
    Assignee: Texas Biotechnology Corp.
    Inventors: Natalie Blok, Chengde Wu, Patricia Woodard, Karin Keller, Timothy Kogan
  • Patent number: 5962490
    Abstract: Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)-furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.
    Type: Grant
    Filed: September 27, 1996
    Date of Patent: October 5, 1999
    Assignee: Texas Biotechnology Corporation
    Inventors: Ming Fai Chan, Chengde Wu, Bore Gowda Raju, Timothy Kogan, Adam Kois, Erik Joel Verner, Rosario Silvestre Castillo, Venkatachalapathi Yalamorri, Vitukudi Narayanaiyengar Balaji
  • Patent number: 5326762
    Abstract: Amides of the formula ##STR1## wherein R.sub.1 and R.sub.2 are independently heteroaryl, X-substituted heteroaryl, X-substituted phenyl, N-substituted triazinyl or N-substituted imidazolyl;and in addition, one of R.sub.1 and R.sub.2 can be as defined above and the other can be phenyl;R.sub.3 is an alkyl chain of 2 to 25 carbon atoms, saturated or unsaturated; an alkyl chain as defined substituted by one or more substituents selected from the group consisting of phenyl, X-substituted phenyl, heteroaryl and X-substituted heteroaryl; an alkyl chain as defined interrupted by one or more groups independently selected from the group consisting of --O--, --S--, --SO--, --SO.sub.2 --, --NH--, --N(lower alkyl)--, --C(O)--, phenylene, X-substituted phenylene, heteroarylene and X-substituted heteroarylene; or an interrupted alkyl chain as defined substituted by one or more substituents selected form the group consisting of phenyl, X-substituted phenyl, heteroaryl and X-substituted heteroaryl;R.sub.
    Type: Grant
    Filed: May 19, 1992
    Date of Patent: July 5, 1994
    Assignee: Schering Corporation
    Inventors: John Clader, Sundeep Dugar, Timothy Kogan, Bradley Tait, Wayne Vaccaro
  • Patent number: 5238935
    Abstract: N-acyltetrahydroisoquinolines including novel compounds of the formula ##STR1## wherein R.sup.1 is a C10-C25 alkyl chain; a substituted C10-C25 alkyl chain; an interrupted C10-C25 alkyl chain; a substituted interrupted C10-C25 alkyl chain; diphenylamino; di-(R.sup.2 -substituted phenyl)amino; di-(heteroaryl)amino; di-(R.sup.2 -substituted heteroaryl)amino; diphenylmethyl; or di-(R.sup.2 -substituted phenyl)methyl;R.sup.2 is hydroxy, lower alkyl, lower alkoxy, halogeno, amino, lower alkylamino or di-(lower alkyl)amino;R.sup.3, R.sup.4 and R.sup.5 are independently H or --(CH.sub.2).sub.n --Ar;Ar is phenyl, R.sup.2 -substituted phenyl, heteroaryl or R.sup.2 - substituted heteroaryl;n=0,1 or 2;m=0,1 or 2;or a pharmaceutically acceptable salt thereof, useful in the treatment of atherosclerosis are disclosed.
    Type: Grant
    Filed: February 20, 1992
    Date of Patent: August 24, 1993
    Assignee: Schering Corporation
    Inventors: Sundeep Dugar, Timothy Kogan